{
    "2016-03-28": [
        "Xtandi price scrutiny hits as Zytiga's strong OS in '302 study helps it in pre-chemo setting. $JNJ can fend off generics ti",
        "Dow #Stocks Trend $GE $MMM $UNH $TRV $WMT $JNJ $KO $IBM $MCD $CAT $UTX $XOM $PG $VZ $MRK $HD $CVX $V $CSCO $AAPL",
        "Notable opening imbalances: $BAC -157K, $C +101K, $KO -149K, $AA +128K, $PFE -55K, $JNJ -31K, $NKE -50K, $WMT -50K, $V"
    ]
}